SBIR/STTR Research Award

Liquid Biopsy for Comprehensive Genetic Profiling in Cancer

Award identifier 0b78a87f77fa5145208c54518f64d187709450eafeff4ee27d7a42b3b1e5d796Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$240,537

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LARIAT BIOSCIENCES, INC.
Proposal award date
2015-04-08
Contract end date
2016-09-30
UEI
Not reported
Solicitation number
PA14-071
Topic code
102

Research abstract

DESCRIPTION provided by applicant Circulating cell free DNA in the bloodstream holds the promise of non invasive andquot liquid biopsiesandquot for cancer diagnostics Mutations that drive the growth and spread of tumors are present and detectable within this genetic pool despite being outnumbered by vast amounts of wild type DNA However there are no single genetic biomarkers of cancer and so to be of practical use many possible mutations must be screened simultaneously Current techniques lose the high sensitivity required for this needle in a haystack search once multiple mutations are targeted Lariat Biosciences is developing new technologies that break this trade off between sensitivity and breadth providing for the first tim the complete tools necessary to mine the bloodstream for clinically actionable signs of cancer The Lariat technology pairs the exquisite sensitivity of emulsion digital PCR capable of mutant quantitation at mutant to wild type ratios of to with the ability to isolate and deepl characterize the detected mutant DNA afterwards With orthogonal methods of DNA identification the false positives that undermine the multiplexed sensitivity of current technique are eliminated Lariatandapos s initial product offering will be a comprehensive genetic screen for the common mutations in EGFR and KRAS a nine plex assay that will be useful for predicting patient response to tyrosine kinase inhibitor drugs and for monitoring emerging resistance to therapy PUBLIC HEALTH RELEVANCE Circulating cell free DNA in the bloodstream holds the promise of noninvasive andquot liquid biopsiesandquot for cancer diagnostics Mutations that drive the growth and spread of tumors are present and detectable within this genetic pool despite being outnumbered by vast amounts of healthy wild type DNA Lariat Biosciences is developing new technologies that provide for the first time the complete tools necessary to mine the bloodstream for clinically actionable signs of cancer

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.